Mirtazapina Teva Italia (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapina Teva Italia, is a Noradrenergic and specific serotonergic antidepressant (NaSSA) presented as a tablet for oral use. It treats major depressive disorder in adult patients. GNH USA supplies Mirtazapina Teva Italia as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine is indicated for depressive disorders and related conditions within the antidepressant therapeutic class.

Major depressive disorder: reduces depressive symptoms and improves mood in adults. Depression with insomnia: helps alleviate sleep disturbances associated with depression. Depression with anxiety: mitigates both depressive and anxiety symptoms in patients.

Mirtazapine may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Drowsiness or sedation - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Peripheral edema

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Seizures - Severe hypotension - Hepatotoxicity - Suicidal thoughts or behavior in young adults - Serotonin syndrome when combined with other serotonergic agents

Before prescribing mirtazapine, clinicians should consider several safety aspects.

Pregnancy: use only if potential benefit justifies potential risk to the fetus. Breastfeeding: assess risk versus benefit for infant exposure. Elderly patients: start at low dose and monitor for sedation. History of bipolar disorder: monitor for mood switching. Concomitant CNS depressants: avoid excessive sedation. Store below 25°C: keep in the original pack, protect from moisture.

Mirtazapine can interact with various medicines, requiring careful management.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis. - Monoamine oxidase inhibitors within 14 days of mirtazapine. - Strong CYP1A2 inhibitors (e.g., fluvoxamine) may increase plasma levels. - Combined use with other serotonergic agents: risk of serotonin syndrome. - CNS depressants (e.g., benzodiazepines, alcohol): profound sedation.

Moderate Interactions (Monitor Closely): - CYP2D6 substrates (e.g., metoprolol): possible altered metabolism. - Antihypertensive agents: additive blood pressure lowering. - Anticholinergic drugs: increased anticholinergic burden. - NSAIDs or anticoagulants: monitor for bleeding risk. - Lithium: monitor for additive CNS effects.